ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

ACCRUED LIABILITIES AND ACCOUNTS PAYABLE

ACCRUED LIABILITIES AND ACCOUNTS PAYABLE

9 Months Ended

Sep. 30, 2024

ACCRUED LIABILITIES AND ACCOUNTS PAYABLE

ACCRUED LIABILITIES AND ACCOUNTS PAYABLE

5.	ACCRUED LIABILITIES AND ACCOUNTS PAYABLE

Accrued liabilities consist of the following:


	September 30,		December 31,
	2024		2023
Legal	$	69,510	$	66,254
Deferred financing costs		—		99,883
Accounting		82,275		101,528
Research and development		578,383		691,908
Severance		172,550		518,704
Other		157,134		28,249
Accrued liabilities	$	1,059,852	$	1,506,526

Accounts payable are current obligations due to vendors. In May 2023, the Company entered into an agreement with a vendor which gave the option to defer payment on approximately $5.5 million of current accounts payable and accrued liabilities until March 31, 2024. As of December 31, 2023, the amount outstanding under the agreement recorded in accounts payable was $5.7 million. The Company made a cash payment of approximately $5.9 million to settle the entirety of the amount outstanding under the agreement in March 2024.